Latest Breaking News On - Stoke therapeutics inc - Page 1 : vimarsana.com

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Stoke Therapeutics, Inc. , a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that.

United statesUnited kingdomStoke therapeutics incAugmentation of nuclear gene outputGoldman sachsStoke therapeuticsAnnual global healthcare conferenceTargeted augmentationNuclear gene output

Stoke Therapeutics (NASDAQ:STOK) Shares Down 4%

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report)’s stock price dropped 4% during mid-day trading on Tuesday . The stock traded as low as $13.75 and last traded at $13.83. Approximately 166,733 shares traded hands during trading, a decline of 82% from the average daily volume of 922,683 shares. The stock had previously closed at […]

United statesJonathan allanCantor fitzgeraldStoke therapeutics incDorsey whitney trustCanaccord genuity groupYork mellon corpJpmorgan chase coSecurities exchange commissionNeedham companyPricet rowe associates incBoard of administration florida retirement systemStoke therapeutics company profileStoke therapeuticsGet free reportGenuity group

Stoke Therapeutics (NASDAQ:STOK) Trading Up 7 2%

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report)’s stock price was up 7.2% during trading on Wednesday . The company traded as high as $16.49 and last traded at $16.46. Approximately 277,244 shares changed hands during trading, a decline of 70% from the average daily volume of 932,838 shares. The stock had previously closed at […]

United statesStephenj tulipanoNeedham companyVanguard group incSecurities exchange commissionStoke therapeutics company profileCapital partnersCantor fitzgeraldStoke therapeutics incRedmile groupJpmorgan chase coStoke therapeuticsGet free reportExchange commissionStoke therapeutics daily

Insider Sale: CEO Edward M Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares

Insider Sale: CEO Edward M Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Stoke therapeutics inc

Encephalopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

DelveInsight s, Encephalopathy Pipeline Insight 2024 report provides comprehensive insights about 70+ Encephalopathy companies and 70+ pipeline drugs in the Encephalopathy pipeline landscape. It.

United statesLas vegasYash bhardwajKnoop biosciencesNeurocrine biosciencesAxcella healthBiosciences incCompany name drugXenon pharmaceuticalsLongboard pharmaceuticalsStoke therapeutics incEncephalopathy xenon pharmaceuticalsDelveinsight business researchXenon pharmaceuticals drugPipeline insightEncephalopathy pipeline report